Whether carrying PIM1 mutations can be regarded as the MCD category and adopting similar treatment strategies as MYD88/CD79B mutations is an important question, because studies have shown that PIM1 point mutations reduce the sensitivity of ABC-DLBCL patients to ibrutinib (Kuo et al., 2016). Here, CD79B is linked to diffuse large B-cell lymphoma.